Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts.

Lee ST, Ji H, Greening DW, Speirs RW, Rigopoulos A, Pillay V, Murone C, Vitali A, Stühler K, Johns TG, Corner GA, Mariadason JM, Simpson RJ, Scott AM.

Growth Factors. 2013 Oct;31(5):154-64. doi: 10.3109/08977194.2013.824435. Epub 2013 Aug 20.

PMID:
23957735
2.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

3.

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.

Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J.

J Natl Cancer Inst. 1993 Aug 18;85(16):1327-33.

PMID:
8340945
4.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
5.

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS.

Cancer Res. 2001 Jul 1;61(13):5090-101.

7.

Amlodipine, a Ca2+ channel blocker, suppresses phosphorylation of epidermal growth factor receptor in human epidermoid carcinoma A431 cells.

Yoshida J, Ishibashi T, Yang M, Nishio M.

Life Sci. 2010 Jan 16;86(3-4):124-32. doi: 10.1016/j.lfs.2009.11.014. Epub 2009 Nov 29.

PMID:
19951711
9.

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2004 Jan 15;10(2):784-93.

10.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.

11.

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.

Cancer Res. 2001 Jul 15;61(14):5355-61.

12.

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G.

Clin Cancer Res. 2006 Jan 15;12(2):577-83.

13.

Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.

Gong JH, Liu XJ, Li Y, Zhen YS.

Cancer Chemother Pharmacol. 2012 May;69(5):1323-32. doi: 10.1007/s00280-012-1827-9. Epub 2012 Feb 5.

PMID:
22311160
14.

In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.

Larbouret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pèlegrin A, Azria D.

Clin Cancer Res. 2007 Jun 1;13(11):3356-62.

16.

Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.

Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G.

J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6.

17.
18.

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.

Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, Virata C, Gamez J, Yco G, Favis M, Wu X, Graff CP, Wang Q, Rohde E, Rennard R, Berquist L, Huang F, Zhang Y, Gao SX, Ho SN, Demarest SJ, Reff ME, Hariharan K, Glaser SM.

MAbs. 2011 May-Jun;3(3):273-88. Epub 2011 May 1.

19.

Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis.

Finetti F, Terzuoli E, Bocci E, Coletta I, Polenzani L, Mangano G, Alisi MA, Cazzolla N, Giachetti A, Ziche M, Donnini S.

PLoS One. 2012;7(7):e40576. doi: 10.1371/journal.pone.0040576. Epub 2012 Jul 18.

20.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

Items per page

Supplemental Content

Write to the Help Desk